Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22581157 | 0.90 | HRH3 (0.36) | HRH3MAPK1MEN1KMT2A | |
| SCHEMBL22581158 | 0.90 | HRH3 (0.36) | HRH3MAPK1MEN1KMT2A | |
| SCHEMBL31237006 | 0.86 | HRH3 (0.39) | HRH3MAPK1MEN1ALDH1A1TSHR | |
| SCHEMBL23945869 | 0.81 | HRH3 (0.40) | HRH3MAPK1MEN1ALDH1A1TSHR | |
| SCHEMBL12002951 | 0.79 | HRH3 (0.44) | HRH3MAPK1MEN1ALDH1A1TSHR | |
| SCHEMBL30015131 | 0.79 | HRH3 (0.34) | HRH3MAPK1HPGDBTK | |
| SCHEMBL1295721 | 0.78 | HRH3 (0.51) | HRH3MAPK1MEN1ALDH1A1TSHR | |
| SCHEMBL186721 | 0.78 | HRH3 (0.51) | HRH3MAPK1MEN1ALDH1A1TSHR | |
| SCHEMBL28492122 | 0.78 | HRH3 (0.51) | HRH3MAPK1MEN1ALDH1A1TSHR | |
| SCHEMBL7675303 | 0.78 | HRH3 (0.43) | HRH3MAPK1MEN1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071586-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-21 | — | — | US | disclosed |
| WO-2009011653-A1 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES AND THEIR US IN THE SYNTHESIS OF SPIROPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | HRH3 129/4885MAPK1 809/4885MEN1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.